XML 22 R9.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenue Recognition Revenue Recognition | 6 Months Ended
--- | ---
Jun. 30, 2019
Text Block [Abstract] |
Revenue Recognition [Text Block] | Revenue recognition The Company’s allowance for doubtful accounts related to performance obligations satisfied in years prior to January 1, 2018 was $29,022 and $52,924 as of June 30, 2019 and December 31, 2018, respectively. There are significant uncertainties associated with estimating revenue, which generally take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues including, without limitation, determination of applicable primary and secondary coverage, changes in patient coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period. As a result of changes in these estimates, additional revenue of $12,617 and $39,795 was recognized during the three and six months ended June 30, 2019, respectively, associated with performance obligations satisfied prior to January 1, 2019. Additional revenue of $8,817 and $76,227 was recognized during the three and six months ended June 30, 2018, respectively, associated with performance obligations satisfied prior to January 1, 2018, which included a benefit of $12,000 and $36,000 for those respective periods from electing to apply Topic 606, Revenue from Contracts with Customers only to contracts not substantially completed as of January 1, 2018. The following table summarizes the Company's segment revenues by primary payor source:
| For the three months ended
| June 30, 2019 |  | June 30, 2018
| U.S. dialysis and related lab services |  | Other - Ancillary services and strategic initiatives |  | Consolidated |  | U.S. dialysis and related lab services |  | Other - Ancillary services and strategic initiatives |  | Consolidated
Patient service revenues: |  |  |  |  |  |  |  |  |  |  |
Medicare and Medicare Advantage | $ | 1,520,193 |  |  | $ |  | $ | 1,520,193 |  |  | $ | 1,526,066 |  |  | $ |  | $ | 1,526,066 |
Medicaid and Managed Medicaid | 160,242 |  |  |  |  |  | 160,242 |  |  | 150,288 |  |  |  |  | 150,288 |
Other government | 110,565 |  |  | 88,770 |  |  | 199,335 |  |  | 110,338 |  |  | 86,530 |  |  | 196,868 |
Commercial | 840,993 |  |  | 33,095 |  |  | 874,088 |  |  | 796,732 |  |  | 19,139 |  |  | 815,871 |
Other revenues: |  |  |  |  |  |  |  |  |  |  |
Medicare and Medicare Advantage |  |  |  | 64,012 |  |  | 64,012 |  |  |  |  | 154,028 |  |  | 154,028 |
Medicaid and Managed Medicaid |  |  |  | 94 |  |  | 94 |  |  |  |  | 16,158 |  |  | 16,158 |
Commercial |  |  |  | 32,307 |  |  | 32,307 |  |  |  |  | 17,006 |  |  | 17,006 |
Other(1) | 5,501 |  |  | 20,670 |  |  | 26,171 |  |  | 4,919 |  |  | 35,034 |  |  | 39,953 |
Eliminations of intersegment revenues | (30,334 | ) |  | (3,403 | ) |  | (33,737 | ) |  | (20,096 | ) |  | (9,189 | ) |  | (29,285 | )
Total | $ | 2,607,160 |  |  | $ | 235,545 |  |  | $ | 2,842,705 |  |  | $ | 2,568,247 |  |  | $ | 318,706 |  |  | $ | 2,886,953 |
(1) | Other consists of management fees and revenue from the Company's ancillary services and strategic initiatives.
| For the six months ended
| June 30, 2019 |  | June 30, 2018
| U.S. dialysis and related lab services |  | Other - Ancillary services and strategic initiatives |  | Consolidated |  | U.S. dialysis and related lab services |  | Other - Ancillary services and strategic initiatives |  | Consolidated
Patient service revenues: |  |  |  |  |  |  |  |  |  |  |
Medicare and Medicare Advantage | $ | 3,013,709 |  |  | $ |  | $ | 3,013,709 |  |  | $ | 3,011,258 |  |  | $ |  | $ | 3,011,258 |
Medicaid and Managed Medicaid | 314,431 |  |  |  |  |  | 314,431 |  |  | 307,783 |  |  |  |  | 307,783 |
Other government | 216,692 |  |  | 173,245 |  |  | 389,937 |  |  | 217,458 |  |  | 169,068 |  |  | 386,526 |
Commercial | 1,629,407 |  |  | 66,483 |  |  | 1,695,890 |  |  | 1,579,711 |  |  | 38,857 |  |  | 1,618,568 |
Other revenues: |  |  |  |  |  |  |  |  |  |  |
Medicare and Medicare Advantage |  |  |  | 125,713 |  |  | 125,713 |  |  |  |  | 296,786 |  |  | 296,786 |
Medicaid and Managed Medicaid |  |  |  | 100 |  |  | 100 |  |  |  |  | 31,949 |  |  | 31,949 |
Commercial |  |  |  | 64,925 |  |  | 64,925 |  |  |  |  | 57,427 |  |  | 57,427 |
Other(1) | 10,406 |  |  | 38,420 |  |  | 48,826 |  |  | 10,033 |  |  | 73,973 |  |  | 84,006 |
Eliminations of intersegment revenues | (60,975 | ) |  | (6,739 | ) |  | (67,714 | ) |  | (38,519 | ) |  | (19,387 | ) |  | (57,906 | )
Total | $ | 5,123,670 |  |  | $ | 462,147 |  |  | $ | 5,585,817 |  |  | $ | 5,087,724 |  |  | $ | 648,673 |  |  | $ | 5,736,397 |
(1) | Other consists of management fees and revenue from the Company's ancillary services and strategic initiatives.
Dialysis and related lab patient service revenues Dialysis and related lab services patient service revenues are recognized in the period services are provided. Revenues consist primarily of payments from Medicare, Medicaid and commercial health plans for dialysis and related lab services provided to patients. A usual and customary fee schedule is maintained for the Company’s dialysis treatments and related lab services; however, actual collectible revenue is normally recognized at a discount from the fee schedule. Other revenues Other revenues consist of the revenues associated with the ancillary services and strategic initiatives, management and administrative support services that are provided to outpatient dialysis centers that the Company does not own or in which the Company owns a noncontrolling interest, and administrative and management support services to certain other non-dialysis joint ventures in which the Company owns a noncontrolling interest.

X
- Definition Revenue Recognition [Text Block] + References No definition available. + Details
Name: | dva_RevenueRecognitionTextBlock
Namespace Prefix: | dva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration